We are live on ! Find out more
BMRN icon

BioMarin Pharmaceuticals
BMRN

438 hedge funds and large institutions have $15.8B invested in BioMarin Pharmaceuticals in 2017 Q4 according to their latest regulatory filings, with 78 funds opening new positions, 150 increasing their positions, 145 reducing their positions, and 44 closing their positions.

New
Increased
Maintained
Reduced
Closed

77% more first-time investments, than exits

New positions opened: 78 | Existing positions closed: 44

34% more call options, than puts

Call options by funds: $208M | Put options by funds: $155M

33% more funds holding in top 10

Funds holding in top 10: 9 → 12 (+3)

7% more funds holding

Funds holding: 411 → 438 (+27)

1.4% more ownership

Funds ownership: 99.72% → 101.12% (+1.4%)

3% more repeat investments, than reductions

Existing positions increased: 150 | Existing positions reduced: 145

3% less capital invested

Capital invested by funds: $16.3B → $15.8B (-$449M)

Holders
438
Holders Change
+27
Holders Change %
+6.57%
% of All Funds
9.93%
Holding in Top 10
12
Holding in Top 10 Change
+3
Holding in Top 10 Change %
+33.33%
% of All Funds
0.27%
New
78
Increased
150
Reduced
145
Closed
44
Calls
$208M
Puts
$155M
Net Calls
+$52.8M
Net Calls Change
+$34.5M

Top Buyers

Rank Fund Capital Flow
1
BBA
Baker Bros. Advisors
New York
+$146M
2
BlackRock
BlackRock
New York
+$81.5M
3
Balyasny Asset Management
Balyasny Asset Management
Illinois
+$60M
4
Citadel Advisors
Citadel Advisors
Florida
+$58.4M
5
Capital Research Global Investors
Capital Research Global Investors
California
+$56.5M

Top Sellers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
-$178M
2
SIG
Senator Investment Group
New York
-$65.1M
3
O
OrbiMed
New York
-$55.9M
4
Jennison Associates
Jennison Associates
New York
-$43.9M
5
Bank of America
Bank of America
North Carolina
-$43.6M
Name Holding Trade Value Shares
Change 		Change in
Stake
CA
426
Calton & Associates
Florida
$3K +$3.74K +43 New
ED
427
Exane Derivatives
France
$2.85K -$12.2K -140 -81%
BFEC
428
Benjamin F. Edwards & Company
Missouri
$2K -$1.3K -15 -36%
EA
429
Edge Advisors
Georgia
$2K – – –
GWM
430
Geneos Wealth Management
Colorado
$2K – – –
OFW
431
Omnia Family Wealth
Florida
$2K – – –
VNA
432
Valley National Advisers
Pennsylvania
$2K – – –
AWA
433
Acorn Wealth Advisors
Michigan
$2K +$1.56K +18 New
SWM
434
SeaCrest Wealth Management
New York
$1K +$783 +9 New
NIM
435
NuWave Investment Management
New Jersey
$1K +$1.13K +13 New
Walleye Trading
436
Walleye Trading
New York
$486 +$420K +4,835 +793%
PCG
437
Private Capital Group
Connecticut
$16 +$217K +2,500 New
SIG
438
Senator Investment Group
New York
– -$65.1M -700,000 Closed
AG
439
Artal Group
Luxembourg
– -$17.4M -200,000 Closed
Credit Agricole
440
Credit Agricole
France
– -$15.8M -169,520 Closed
HCM
441
Highbridge Capital Management
New York
– -$9.61M -103,300 Closed
TCM
442
Tang Capital Management
California
– -$8.4M -90,215 Closed
WG
443
Winton Group
United Kingdom
– -$8.35M -89,673 Closed
CCI
444
Columbus Circle Investors
– -$7.84M -84,232 Closed
Squarepoint
445
Squarepoint
New York
– -$5.17M -55,529 Closed
JCP
446
Jabre Capital Partners
Switzerland
– -$4.19M -45,000 Closed
SCA
447
Secor Capital Advisors
New York
– -$3.16M -33,972 Closed
SCM
448
Stevens Capital Management
Pennsylvania
– -$1.87M -20,048 Closed
Nomura Holdings
449
Nomura Holdings
Japan
– -$1.84M -19,762 Closed
HHC
450
Hutchin Hill Capital
New York
– -$1.81M -19,400 Closed
16 17
18
19 20

BMRN Hedge Fund Activity: Q4 2017 in Review

438 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in BioMarin Pharmaceuticals (BMRN) for Q4 2017, worth a combined $15.8B — down 2.8% from $16.3B a quarter earlier.

Buyers outnumbered sellers: 78 funds opened new BMRN positions and 44 closed out — a net gain of 34 holders — while 150 added to existing stakes and 145 trimmed.

The largest buyer was Baker Bros. Advisors, adding an estimated $146M. The largest seller was Fidelity Investments, cutting an estimated $178M.

  • 438 institutional investors held BioMarin Pharmaceuticals (BMRN) as of Q4 2017, up from 411 in Q3 2017.
  • Funds reported $15.8B of BioMarin Pharmaceuticals stock for Q4 2017, down 2.8% quarter-over-quarter.
  • 78 funds opened new BioMarin Pharmaceuticals positions in Q4 2017 and 44 closed out, a net change of +34 holders.
  • The largest BioMarin Pharmaceuticals buyer in Q4 2017 was Baker Bros. Advisors, an estimated $146M added.
  • The largest BioMarin Pharmaceuticals seller in Q4 2017 was Fidelity Investments, an estimated $178M sold.

Based on aggregated 13F filings for Q4 2017.